BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: A study of 653 patients

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18346-18355

  Jin, Langping ^a   Chen, Endong ^a   Dong, Siyang ^a   Cai, Yefeng ^a   Zhang, Xiangjian ^a   Zhou, Yili ^a   Zeng, Ruichao ^a   Yang, Fan ^a   Pan, Chuanmeng ^a   Liu, Yehuan ^a   Wu, Weili ^a   Xing, Mingzhao ^b   Zhang, Xiaohua ^a   Wang, Ouchen ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF V600E mutation; Molecular marker; Papillary thyroid carcinoma; Prognosis; TERT promoter mutation

Indexed keywords

B RAF KINASE; GENOMIC DNA; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CAPSULAR INVASION; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; EXTRATHYROIDAL INVASION; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PROMOTER REGION; TERT GENE; THYROID CARCINOMA; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WILD TYPE; CARCINOMA; GENETICS; MUTATION; THYROID TUMOR;

CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; THYROID NEOPLASMS;

EID: 84975506138     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7811     Document Type: Article

References (45)

1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140:317-322
2. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E. Thyroid cancer mortality and incidence:A global overview. International journal of cancer. 2015; 136:2187-2195
3. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer:the influence of access to care. Thyroid. 2013; 23:885-891
4. Brito JP, Morris JC, Montori VM. Thyroid cancer:zealous imaging has increased detection and treatment of low risk tumours. Bmj. 2013; 347:f4706
5. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute. 2003; 95:625-627
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer research. 2003; 63:1454-1457
7. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22:4578-4580
8. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The Journal of clinical endocrinology and metabolism. 2005; 90:6373-6379
9. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study. The Journal of clinical endocrinology and metabolism. 2008; 93:3943-3949
10. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas:correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 2009; 115:972-980
11. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, et al. The BRAF(V600E) Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma:Single-Institution Results from a Large Cohort Study. J Clin Endocr Metab. 2012; 97:4390-4398
12. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013; 309:1493-1501
13. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. Journal of clinical oncology. 2015; 33:42-50
14. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population:its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine journal. 2009; 56:89-97
15. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? American journal of surgery. 2012; 203:436-441
16. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma:data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006; 13:455-464
17. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid Microcarcinoma. Annals of surgical oncology. 2010; 17:3294-3300
18. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014; 33:4978-4984
19. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. The Journal of clinical endocrinology and metabolism. 2014; 99:E1130-1136
20. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. The Journal of clinical endocrinology and metabolism. 2014; 99:E754-765
21. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of clinical oncology. 2014; 32:2718-2726
22. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B, Simoni M, Bulfamante G, Vicentini L, et al. Telomerase in differentiated thyroid cancer:promoter mutations, expression and localization. Molecular and cellular endocrinology. 2015; 399:288-295
23. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339:957-959
24. Horn S, Figurel A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339:959-961
25. Killela PJ, Reitman ZJ, Jiao YC, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He YP, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013; 110:6021-6026
26. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013; 110:17426-17431
27. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Moller I, Schwamborn M, Sucker A, Hillen U, Badenas C, et al. TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute. 2014; 106
28. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer. 2013; 20:603-610
29. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer:higher prevalence in advanced forms of the disease. The Journal of clinical endocrinology and metabolism. 2013; 98:E1562-1566
30. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, et al. Frequency of TERT promoter mutations in human cancers. Nature communications. 2013; 4:2185
31. Zheng W, Zhang Z. An analysis of cancer incidence in 2005 in Lucheng District, Wenzhou City, Zhejiang Province. Bulletin of Chinese Cancer. 2007; 16:306-308
32. Gong W, Hu R, Luo S, Jin P, Fei F, He Q, Zhang Z, Min Y. Analysis on incidence and mortality characteristics of thyroid cancer during 2007 to 2011 in Zhejiang Province. Zhejiang Prev Med. 2014; 26:433-437
33. Yang L, Zheng R, Wang N, Zhang S, Chen W. Analysis of incidence and mortality of thyroid cancer in China, 2010. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2014; 48:663-668
34. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159:676-690
35. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis. Cancer. 2012; 118:1764-1773
36. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid:a meta-analysis. Cancer. 2007; 110:38-46
37. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment:a systematic review and metaanalysis. Medicine. 2012; 91:274-286
38. Guan HX, Ji MJ, Bao R, Yu HY, Wang YG, Hou P, Zhang Y, Shan ZY, Teng WP, Xing MZ. Association of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer. J Clin Endocr Metab. 2009; 94:1612-1617
39. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E. Higher rate of BRAF mutation in papillary thyroid cancer over time:a single-institution study. Cancer. 2011; 117:4390-4395
40. Kim SJ, Myong JP, Jee HG, Chai YJ, Choi JY, Min HS, Lee KE, Youn YK. Combined effect of Hashimoto's thyroiditis and BRAF mutation status on aggressiveness in papillary thyroid cancer. Head & neck. 2014 Sep 12. doi:10.1002/hed.23854
41. Kwak HY, Chae BJ, Eom YH, Hong YR, Seo JB, Lee SH, Song BJ, Jung SS, Bae JS. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis? Int J Clin Oncol. 2015; 20:463-473
42. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma:development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114:1050-1057
43. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 2010; 107:10649-10654
44. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer:a functional link to drive cancer progression. Cancer Res. 2011; 71:2417-2422
45. Nucera C. Targeting thyroid cancer microenvironment:basic research and clinical applications. Front Endocrinol (Lausanne). 2013; 4:167